A panelist discusses how Matching-Adjusted Indirect Comparison (MAIC) analyses are limited by potential unmeasured confounding factors, small effective sample sizes after matching, and reliance on ...

A panelist discusses how MAIC (Matching-Adjusted Indirect Comparison) methodology addresses the lack of head-to-head clinical trials in metastatic hormone-sensitive prostate cancer (mHSPC) by ...

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, ...

“I feel a lot of providers, with Antiva being available, have unfortunately reserved use of this great FDA-approved agent for BCG-unresponsive patients because of the supply issue with BCG," says ...

The SureForm 45 stapler is the first stapler cleared for single-port robotic surgery in the US, enhancing surgical control and efficiency. SmartFire technology in the stapler optimizes staple line ...

Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices? What challenges do you anticipate in operationalizing TAR-200 and other novel delivery ...

A polygenic risk score identified more clinically significant prostate cancer cases than PSA or MRI in the BARCODE1 trial. The study involved 6393 participants, with 745 invited for screening based on ...

Experts discuss the unmet needs in the treatment of non–muscle-invasive bladder cancer (NMIBC), highlighting areas where advancements are still needed.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology. The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an ...

"We should not be preemptively reducing the dose for all our patients, because half of the patients will never develop grade 3/4 anemia," says Neeraj Agarwal, MD, FACS. Data from the phase 3 TALAPRO-2 ...

“The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant setting," says Joshua J. Meeks, MD, PhD. “The NIAGARA approval really begins to bring immunotherapy into the neoadjuvant ...

“I think it's primarily due to dietary changes that are more and more prevalent regardless of sex,” says Ian Metzler, MD, MTM. “We were always taught that the breakdown is usually more towards men in ...